EGF receptor activation decreases retroviral gene transfer through protein kinase C-delta

Area of Science:

• Molecular Biology
• Virology
• Cell Biology

Background:

• Retrovirus vector design has advanced, but host cell interactions are not fully understood.
• Recombinant retroviruses struggle to transduce non-dividing cells, leading to research on growth factors and extracellular matrix molecules to improve gene transfer efficiency.

Purpose of the Study:

• To investigate the role of Epidermal Growth Factor Receptor (EGFR) signaling in modulating retroviral gene transfer into host cells.
• To elucidate the specific molecular pathways, including protein kinases, involved in EGFR-mediated regulation of retroviral transduction.

Main Methods:

• Treatment of human epidermal keratinocytes and various cell lines with EGFR ligands (EGF, TGF-α, HB-EGF) or an EGFR function-blocking antibody.
• Inhibition of EGFR tyrosine phosphorylation and specific protein kinase C (PKC) isoforms (PKC-delta, PKC-zeta) using chemical inhibitors and small interfering RNA (siRNA).
• Assessment of retroviral gene transfer efficiency and cell cycle status using flow cytometry and cell cycle analysis.

Main Results:

• EGFR ligands (EGF, TGF-α, HB-EGF) significantly decreased retroviral gene transfer efficiency.
• Inhibition of EGFR signaling, via blocking antibodies or tyrosine phosphorylation inhibitors, dose-dependently enhanced gene transfer.
• Blocking PKC-delta, but not PKC-zeta, reversed the inhibitory effect of EGF, implicating PKC-delta in the EGFR-mediated pathway.
• The observed effects of EGFR activation on retroviral gene transfer were independent of the target cells' cell cycle status.

Conclusions:

• EGFR signaling negatively regulates retroviral gene transfer, mediated through the activation of PKC-delta.
• These findings provide new insights into retrovirus-host cell interactions and have potential implications for optimizing retroviral gene therapy vectors.
• Understanding the role of EGFR and PKC-delta could inform the design of novel antiretroviral therapies.